Abstract 1404P
Background
Sotorasib is the first specific and irreversible KRAS G12C inhibitor that showed superiority vs docetaxel in CodeBreaK 200 phase 3 study, with a median PFS of 5.6 mos (HR: 0,66) and an acceptable safety profile for sotorasib. In France, sotorasib has been authorized before MA for patients with KRAS G12C mNSCLC who progressed after at least one treatment line. Here, we present the clinical characteristics of patients included in the cATU.
Methods
From 08/2021 to 06/2022, data from 1011 pts, of which 958 received sotorasib, were collected in 249 centers.
Results
Main characteristics of this population are presented below: Table: 1404P
Variable | Results |
Median age, years [Q1-Q3] n=1011 | 65.9 [58.8-72] |
Male, % n=1011 | 58.7 |
Smoking status Non / former / current, % n=1009 | 3.6 / 79.4 / 17 |
Adenocarcinoma, % n=1004 | 94.8 |
ECOG PS, % n=1011 0 1 ≥2 | 20 58.9 21.2 |
PD-L1, % n=1010 <1 [1-49] ≥50 Undetermined | 40.9 30.2 21.8 7.1 |
KRAS testing by NGS, % n=1010 | 84.1 |
Brain metastases (active), % n=1011 | 29.4 (10.1) |
Sotorasib therapy line 2 / 3 / ≥4, % n=997* | 53.3 / 27.1 / 19.6 |
Median of prior lines n=1004 | 1 |
First-line therapy, % n=997 CT IO CT+IO | 33.9 12.7 48.6 |
*39 pts didn’t receive sotorasib at all 80% of patients were exposed to chemotherapy (CT) and immunotherapy (IO) before sotorasib: ∼50% simultaneously, ∼30% sequentially. 51% of patients received sotorasib directly after IO. With a median follow-up of 8.9 [0.2-17.5] mos, the median duration of treatment was 8.1 [0.1-17.5] mos. These data must be interpreted with caution because of the short follow-up period.
.Conclusions
Nearly 1000 pts, ineligible to clinical trials, were treated by sotorasib through French cATU, highlighting the unmet therapeutic need. The main technique to retrieve KRASG12C was NGS. Clinical characteristics are consistent with those of CodeBreaK 200 trial pts, with a relatively lower proportion of patients with PD-L1≥50%. More than half of the patients received sotorasib in 2L, reflecting conditional marketing authorization granted in Europe. Real-life data on sotorasib efficacy, safety and QoL are currently studied by academic institutions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Amgen SAS.
Funding
Amgen SAS.
Disclosure
H. Lena: Financial Interests, Personal, Advisory Board: MBS, Roche, MSD, Pfizer, AZ, Lilly, Takeda, Amgen. J. Cadranel: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, BMS, MSD, Novartis, Sanofi, Takeda, Pfizer, Amgen, Lilly; Financial Interests, Institutional, Funding: AbbVie, Pfizer. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Non-Financial Interests, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Family member is an employee: AstraZeneca. J. Mazieres: Financial Interests, Personal, Invited Speaker: AZ, Roche, BMS, MSD, daiichi, Novartis, Amgen; Financial Interests, Personal, Advisory Board: Roche, AZ, Pierre Fabre, Takeda, BMS, MSD, Jiangsu Hengruii, Blueprint, Daiichi, Novartis, Amgen, Lillly, Merck; Financial Interests, Institutional, Research Grant: Roche, AZ, PF, BMS; Non-Financial Interests, Institutional, Principal Investigator: Roche, AZ, PF, Takeda, BMS, MSD, Jiangsu Hengruii, Blueprint, Daiichi, Novartis, Amgen, Sanofi, Pfizer, Merck. H. Curcio: Financial Interests, Personal, Invited Speaker: Viatris. A. Madroszyk Flandin: Financial Interests, Personal and Institutional, Advisory Board: AZ, Roche. J.B. Auliac: Non-Financial Interests, Personal, Advisory Board: AZ, BI, BMS, Roche; Non-Financial Interests, Personal, Invited Speaker: Sanofi, Takeda. O. Bylicki: Financial Interests, Personal, Advisory Board: BMS, Roche, Takeda, MSD, AZ, Janssen. S. Couraud: Financial Interests, Personal, Advisory Board: Amgen, AZ, BMS, MSD, Roche, Takeda, Sanofi, Fabentech; Financial Interests, Institutional, Funding: Chugai, Novartis, Amgen, AZ, BMS, MSD, Roche, Takeda, Bayer, Sanofi, Janssen; Financial Interests, Personal, Invited Speaker: AZ, Pfizer; Financial Interests, Institutional, Research Grant: AZ, Chugai, Takeda; Financial Interests, Personal, Other: Laidet. F. Barlesi: Financial Interests, Institutional, Advisory Board: AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Sanofi Aventis, Seattle Genetics, Takeda, AbbVie, Acea, Amgen, Eisai, Ignyta; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Merck, Pierre Fabre, F. Hoffmann-La Roche Ltd., Innate Pharma, Mirati. E. Pichon: Financial Interests, Personal, Research Grant: Mirati, BMS, Janssen, AZ, BeiGene, GSK; Financial Interests, Personal, Advisory Board: Takeda. A. Métivier: Financial Interests, Personal, Training: BMS, MSD, Takeda; Financial Interests, Personal, Sponsor/Funding: Novartis, Pfizer. B. Duchemann: Financial Interests, Personal, Expert Testimony: AZ, BMS, Amgen, Lilly; Financial Interests, Personal, Invited Speaker: Roche, Chiesi; Financial Interests, Personal, Other: Oxyvie. L. De Gunten: Financial Interests, Personal, Full or part-time Employment: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
1379P - Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations
Presenter: Jin-Ji Yang
Session: Poster session 20
1380P - Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial
Presenter: Santiago Viteri
Session: Poster session 20
1381P - TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION
Presenter: Petros Christopoulos
Session: Poster session 20
1382P - Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib
Presenter: Christian Rolfo
Session: Poster session 20
1383P - Efficacy of capmatinib compared to standard of care for German patients with locally advanced or metastatic NSCLC harboring METex14 mutations: Results from the RECAP study
Presenter: Anna Kron
Session: Poster session 20
1384P - Phase II study of cabozantinib in patients with MET-altered lung cancers
Presenter: Guilherme Harada
Session: Poster session 20
1385P - Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
Presenter: Monica Chen
Session: Poster session 20
1386P - Validation of MET amplification using next-generation sequencing in lung adenocarcinoma
Presenter: Marta Salido
Session: Poster session 20
1387P - Efficacy of first-line treatment options in advanced HER2-altered non-small cell lung cancer: A multi-center retrospective study
Presenter: haifeng sun
Session: Poster session 20
1388P - Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)
Presenter: Shirish Gadgeel
Session: Poster session 20